Press release on Impactiviti’s PharmaCentral portal.
Glaxo’s Avandia “problem” is all over the news this week. It’s still to be determined how much is smoke, and how much is fire. This Business Week article at least tries to provide some counter-balance to the hype. One thing is for sure – the tort lawyers are firing up the engines and loving this new opportunity for ambulance-chasing.
The battering being taken by anemia drugs is definitely impacting Roche’s potential new entry, Mircera.
In the ongoing saga over at Pfizer, two high-level departures announced this week. There may or may not be a connection to recent revelations over at Peter Rost’s Question Authority blog.
AstraZeneca and the pursuit of large molecules.
Wyeth gets approval for Lybrel, a new contraceptive for putting the menstrual cycle on hold.
Possible problems with Novartis’ innovative treatment for iron overload (Exjade).
UCB – encouraging data for new treatment for Crohn’s disease.
A PhRMA spin on rep-doctor influence, published by the Boston Globe.
Leave a Reply